Compare NEN & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
Current Price
Current Price
| Metric | NEN | SGHT |
|---|---|---|
| Founded | 1977 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 227.9M | 235.0M |
| IPO Year | 1995 | 2021 |
| Metric | NEN | SGHT |
|---|---|---|
| Price | $59.00 | $4.96 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $9.08 |
| AVG Volume (30 Days) | 759.0 | ★ 329.2K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.71% | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $89,196,544.00 | $77,363,000.00 |
| Revenue This Year | N/A | $11.67 |
| Revenue Next Year | N/A | $10.39 |
| P/E Ratio | $19.68 | ★ N/A |
| Revenue Growth | ★ 10.76 | N/A |
| 52 Week Low | $56.00 | $3.11 |
| 52 Week High | $79.00 | $9.24 |
| Indicator | NEN | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 45.84 | 58.01 |
| Support Level | $56.00 | $4.86 |
| Resistance Level | $66.30 | $5.25 |
| Average True Range (ATR) | 0.85 | 0.39 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 40.08 | 60.84 |
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.